Key insights
- BD received CE Mark for its Liverty TIPS Stent Graft in Europe, enabling commercialization for treating complications from portal hypertension. While positive for BD's revenue outlook, the device is still investigational in the US. BD's strong financial health and dividend history may provide some support to its stock price.
FRANKLIN LAKES, N.J. - BD (NYSE:BDX) announced Tuesday it received CE Mark approval for its Liverty TIPS Stent Graft, enabling commercialization across the European Union for treating complications from portal hypertension in patients with cirrhosis. The $44 billion medical technology company, a prominent player in the Healthcare Equipment & Supplies industry, currently trades below its InvestingPro Fair Value, suggesting potential upside for investors. BD maintains a strong financial health score and has raised its dividend for 55 consecutive years.
The device features an adjustable inner diameter ranging from 6-10 mm and offers multiple covered stent lengths for transjugular intrahepatic portosystemic shunt procedures. The stent graft uses a self-expanding nitinol frame with dual-layer ePTFE encapsulation and carbon impregnation on the inner surface, delivered through a triaxial delivery system.
TIPS procedures reduce portal pressure to alleviate symptoms in patients with cirrhosis, including variceal bleeding and fluid accumulation. According to the Global Burden of Disease study, approximately 58 million people worldwide live with cirrhosis.
BD stated that safety and effectiveness data from its ARCH clinical trial will be presented at the Society of Interventional Radiology Annual Scientific Meeting on April 12, 2026. The ARCH study is a global, prospective, multi-center, single-arm trial evaluating the device for treating portal hypertension complications.
Prof. Ziv Haskal, the study’s global principal investigator, will present the trial results. The company stated the trial provides prospective data on small diameter calibrated TIPS for treating major complications of portal hypertension.
The device remains investigational in the United States and is limited to investigational use only under U.S. law.
The information is based on a press release statement from BD. The company employs more than 60,000 people globally and manufactures medical technology products.
In other recent news, Becton Dickinson reported its fiscal first-quarter 2026 results, showing ex-foreign exchange revenue growth of 0.4% year-over-year, surpassing its own guidance of low-single-digit declines. This performance led RBC Capital to adjust its price target for the company to $172 from $210, while maintaining a Sector Perform rating. Similarly, Argus lowered its price target on Becton Dickinson shares to $180 from $230, citing market turbulence, though it continues to support the company’s strategic focus on its Medical and Interventional segments.
Additionally, Becton Dickinson received FDA clearance for its Surgiphor 1000mL antimicrobial irrigation system, which is designed to aid in surgical procedures by removing debris and microorganisms from wounds. In another development, the company announced tender offers to purchase up to $1.6 billion of its outstanding debt across 15 different series. These offers prioritize the 6.700% Senior Notes due 2026, and include specific subcaps for other series.
Meanwhile, Raymond James noted that medical technology pricing has remained flat in 2025, following a brief positive trend in 2023 and 2024. This trend, largely unaffected by pricing changes, has had little impact on overall revenue growth for the sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.